Close
Nordic 9Nordic 9

AixThera (investor - Others)

Ireland aixthera.com
See something wrong or missing? Let us know
Offices:Dublin

AixThera is an Irish investment vehicle formed to invest in the development of new therapeutics with the potential to positively impact patient lives.

Average round investment:30M USD
Average number per year:1.0
Distribution: 2022 (1)
Portfolio companies: United Kingdom Ochre Bio
Mostly invests in: United Kingdom United Kingdom (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to AixThera

Name Criteria
Hong Kong CR-CP Life Science Fund
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Canada Inovia Capital
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Inflexion Private Equity
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Evotec AG
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
China GT Healthcare Capital
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Rick Klausner
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan UTokyo IPC
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Kyoritsu Holdings
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Digitalis Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom ALSA Ventures
73%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top